Physician profile
Ryan D Matherly
NPI 1356344972
$1,526.21
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $364.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $141.54 | 2019 | |
| Novo Nordisk INC | $139.38 | 2019 | |
| Sunovion Pharmaceuticals INC. | $134.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $110.03 | 2019 | |
| Abbvie INC. | $80.30 | 2019-2020 | |
| Pfizer INC. | $64.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.40 | 2019 | |
| Astellas Pharma US INC | $48.22 | 2019-2020 | |
| Allergan, INC. | $41.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.62 | 2019-2020 | |
| Amarin Pharma, INC. | $35.77 | 2020 | |
| Alkermes, INC. | $29.53 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.68 | 2020 | |
| Lilly USA, LLC | $24.14 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $19.67 | 2019 | |
| Adlon Therapeutics L.P. | $17.15 | 2019 | |
| Vyera Pharmaceuticals, LLC | $12.62 | 2019 | |
| Sanofi Pasteur INC. | $12.39 | 2019 | |
| Mdd US Operations, LLC | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Matherly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.